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Abstract
Insulin resistance in metabolic syndrome subjects is profound in spite of muscle insulin receptor and insulin-responsive glucose transporter (GLUT4)
expression being nearly normal. Insulin receptor tyrosine kinase phosphorylation of insulin receptor substrate-1 (IRS-1) at Tyr896 is a necessary step in
insulin stimulation of translocation of GLUT4 to the cell surface. Serine phosphorylation of IRS-1 by some kinases diminishes insulin action in mice. We
evaluated the phosphorylation status of muscle IRS-1 in 33 subjects with the
metabolic syndrome and seventeen lean controls. Each underwent euglycemic
insulin clamps and a thigh muscle biopsy before and after 8 weeks of either
strength or endurance training. Muscle IRS-1 phosphorylation at six sites was
quantified by immunoblots. Metabolic syndrome muscle IRS-1 had excess
phosphorylation at Ser337 and Ser636 but not at Ser307, Ser789, or Ser1101.
Ser337 is a target for phosphorylation by glycogen synthase kinase 3 (GSK3)
and Ser636 is phosphorylated by c-Jun N-terminal kinase 1 (JNK1). Exercise
training without weight loss did not change the IRS-1 serine phosphorylation.
These data suggest that baseline hyperphosphorylation of at least two key serines within muscle IRS-1 diminishes the transmission of the insulin signal
and thereby decreases the insulin-stimulated translocation of GLUT4. Excess
fasting phosphorylation of muscle IRS-1 at Ser636 may be a major cause of
the insulin resistance seen in obesity and might prevent improvement in insulin responsiveness when exercise training is not accompanied by weight loss.

Physiol Rep, 2 (12), 2014, e12236,
doi: 10.14814/phy2.12236
This project is listed in ClinicalTrials.Gov as
NCT00727779.

Background
After decades with a stable prevalence of obesity in the
United States, there has been a steady increase in adult
obesity rates beginning the 1980s (Flegal et al. 2010). The
percentage of Americans who are obese more than doubled between 1980 and 2000. The prevalence of diagnosed
diabetes increased by more than 150% over the same period (Polonsky 2012). More than half of all adults are now
overweight (BMI > 25 kg/m2), with some regions of the

United States having in excess of two-thirds of the population being overweight or obese (BMI > 30 kg/m2).
Because of obesity-related illness, the average life expectancy in the United States may soon decline for the first
time (Bray and Bellanger 2006). The preventable excess
obesity-related mortality is projected to soon exceed that
associated with cigarette smoking. Insulin resistance and
hyperinsulinemia are key elements of the Metabolic Syndrome that is marked by visceral obesity, hypertension,
hyperlipidemia, hyperglycemia, and coronary heart disease
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(Grundy et al. 2004; Kahn et al. 2005). The metabolic
syndrome is considered to be prediabetes and effective
preventive measures are urgently being sought (Kahn
et al. 2005). The mechanism of the severe insulin resistance in the metabolic syndrome remains unclear.
The next intracellular step in insulin action after activation of the cell surface insulin receptor tyrosine kinase is
phosphorylation of insulin receptor substrate-1 (IRS-1)
on a specific tyrosine residue (Saltiel and Kahn 2001).
However, there are many additional sites in IRS-1 that
are phosphorylated by several other intracellular serine/
threonine protein kinases.
Studies of insulin receptor substrate-1 (IRS-1) phosphorylation in mice have demonstrated a status of
chronic low-grade inflammation associated with adipose
tissue cytokine production in obesity (McCurdy and
Klemm 2013). The IKKb/NFjB inflammatory cascade has
been shown to cause phosphorylation of IRS-1 at Ser307
and diminish insulin signaling (Gao et al. 2002). Cytokine
activation of the JAK STAT pathway is associated with
IRS-1 phosphorylation at Ser636 and Ser307 (Johnston
et al. 2003). Activation of mTOR and S6K1 is also associated with phosphorylation of Ser636 and Ser307. Strength
training exerts its effect on muscle fiber hypertrophy
through activation of mTOR and resultant phosphorylation of downstream targets (Frost and Lang 2011), but
mTOR-mediated phosphorylation of IRS-1 Ser636 inhibits insulin action in mice (Ozes et al. 2001).
These studies of IRS-1 phosphorylation in mice suggest
that the obesity of the metabolic syndrome might result
in insulin resistance via obesity-related chronic inflammation and activation of the JNK1 pathway and the IKKNFkB cascade causing serine phosphorylation of IRS-1 at
Ser307 and Ser636. Exercise training could modify the
basal IRS-1 phosphorylation status at Ser636 and/or
Ser789 via activation of mTOR and AMPK. The studies
reported here evaluated the phosphorylation status by immunoblots of muscle IRS-1 at key serines in untrained
metabolic syndrome subjects and quantified those again
post training.

Research design and Methods

subjects met the criteria for metabolic syndrome (Kahn
et al. 2005) because they also had waist circumference
greater than 40 inches, insulin resistance documented by
euglycemic clamp, and dyslipidemia (low HDL cholesterol, high triglycerides, or high LDL cholesterol). Each of
the subjects provided written valid consent approved by
the East Tennessee State University Institutional Review
Board.

The exercise intervention
Thirty-two volunteers (including 22 metabolic syndrome
subjects) participated in increasing intensity strength
training without weight loss for 8 weeks as previously
described (Layne et al. 2011). Eighteen additional participants (11 metabolic syndrome subjects) were subjected to
increasing intensity and duration endurance training on
stationary bicycles for 8 weeks with no weight loss permitted. The amount of energy expended each week by the
subjects in each of the two exercise training protocols was
closely matched throughout the 8 weeks based on time
and intensity. Estimated exercise-related energy expenditure began at 250 kcal per day and peaked at 450 kcal per
day in week 7.

Anthropometric assessments
Each subject underwent measurement of body composition and insulin responsiveness. A percutaneous muscle
biopsy was performed just prior to the euglycemic clamp
study.
Muscle biopsies
A small sample (100–150 mg) of thigh muscle was
obtained. Percutaneous needle biopsies of vastus lateralis
were performed after an overnight fast and 2 hours of
quiet recumbency as previously described Stuart et al.
(2006). The sample was immediately divided into two
pieces, one of which was mounted on cork and frozen in
an isopentane slurry and the other was frozen in liquid
nitrogen for later processing.

Subject selection

Euglycemic hyperinsulinemic clamp

Fifty subjects participated in this study. Subjects with diabetes were excluded. Thirty-three subjects deemed to be
at high risk for diabetes were recruited meeting the entry
criteria of obesity (BMI > 30 kg/m2) and a close family
member having type 2 diabetes. The other 17 subjects
were sedentary controls who were nonobese without a
family history of diabetes. None of the subjects engaged
in regular exercise for at least 1 year. All of the obese

Immediately following the muscle biopsy, an insulin
clamp was performed. After a 2-hour baseline period, an
insulin infusion at 40 mU/m2/min was performed for 2
hours to achieve a physiological insulin concentration of
about 50 lU/mL and a stable glucose infusion rate
(SSGIR) to quantify insulin sensitivity (Reeds et al. 2006).
Fasting serum glucose and insulin concentration were
determined as part of the euglycemic clamp procedure.
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Body composition
Body fat and lean body mass were measured by air displacement plethysmography (BodPod, Concord, CA).

Quantification of muscle content of total
and phosphorylated insulin receptor
substrate-1 (IRS-1) by immunoblots
Muscle was homogenized and subjected to polyacrylamide
gel electrophoresis through Tris-acetate 3–8% gradient
gels (Invitrogen, Carlsbad, CA) as previously described
(Layne et al. 2011). After transfer to membranes and
blocking with buffer containing bovine serum albumin
(Cell Signaling, Danvers, MA), incubations overnight with
primary antibodies directed against the epitope of interest
were performed. Antibodies against IRS-1 pSer337
(#2580) and pSer789 (#2389) were obtained from Cell
Signaling. Antibodies were obtained from Abcam (Cambridge, MA) that were specific for total IRS-1 (ab52167),
pTyr896 (ab4873), pSer307 (ab1194), pSer636 (ab53038),
and pSer1101 (ab55343). Second antibody with enhanced
chemiluminescence using SuperSignal West Pico Chemiluminescence substrate (Pierce, Rockford, IL) was subsequently added and images were generated using a G-BOX
from Syngene (Frederick, MD). The relative intensity of
the digital signal intensity was quantified using QuantityOne software from Bio-Rad (Hercules, CA).

Statistical calculations
All data are displayed as mean  standard error, except
as explicitly indicated. Comparing data between the two
groups was performed using the independent t test except
as noted. Pretraining and post-training comparisons were
made using the paired t test. Relationships between select
variables were assessed using Pearson Product Moment
Correlation. Statistical procedures were performed using
SigmaPlot version 12.2 from Systat Software (San Jose,
CA).

Results
Insulin resistance in metabolic syndrome
subjects
All of the metabolic syndrome subjects were insulin resistant. The steady-state glucose infusion rate (SSGIR) determined by the euglycemic insulin clamp studies averaged
38% of that of the sedentary control subjects (Table 1).
Fasting insulin concentration was double that of the controls. Fasting serum glucose was higher in the metabolic
syndrome group. Table 1 displays several other pertinent

Muscle IRS-1 in the Metabolic Syndrome

characteristics of the subjects with BMI, waist circumference, lean body mass, and fat mass all being greater in
the metabolic subject group. VO2max was less than controls. Fasting triglycerides and LDL cholesterol were
increased and HDL cholesterol was decreased in the metabolic syndrome subjects. Serum alkaline phosphatase (AP)
was quantified as an indirect indicator of hepatic steatosis. Metabolic syndrome AP was increased, although
serum AST and ALT hepatocellular enzymes were not
increased (data not shown).

Muscle IRS-1 pretraining baseline
phosphorylation
The total IRS-1 content and the amount of phosphorylated IRS-1 at several specific sites on the molecule were
determined using specific antibodies in immunoblots.
Total IRS-1 content of muscle was not different in the
metabolic syndrome subjects as displayed in Fig. 1B.
Phosphorylation of tyrosine at position 896 (Tyr896) was
not different and the ratio of phosphorylation at Tyr896
to total IRS-1 averaged 17% less in the metabolic syndrome, but this decrease in the ratio was not statistically
significant. Phosphorylation at Ser307, Ser789, and
Ser1101 did not differ between the groups, but the phosphorylation at Ser337 and Ser636 were significantly more
in the metabolic syndrome group.

The effect of exercise training of the excess
phosphorylation of IRS-1 at Ser337 and
Ser636
The protocols of exercise training that were used in these
studies did not alter the insulin responsiveness of metabolic syndrome subjects or controls as quantified by
euglycemic clamp studies (metabolic syndrome post training 2.16  0.28 mg/kg.min, P = 0.685; controls post
training 6.85  0.81 mg/kg.min, P = 0.354). Fasting insulin concentrations did not change either (metabolic syndrome post training 128  28 pmol/L; controls post
training 31  4 pmol/L).
Exercise training for 8 weeks without weight loss did
not change the fasting phosphorylation status of muscle
IRS-1 at Ser337 and Ser636 (Fig. 2). In both groups, there
was a trend toward 10–20% increases in the phosphorylation status at Ser789, and Ser1101, but no change in
phospho-Ser307.
Phosphorylation at muscle IRS-1 Ser636 inversely correlated with SSGIR as shown in Fig. 3. The data displayed
in the figure include both pretraining and posttraining
muscle biopsies. Analyzing the correlation in the controls
alone or the metabolic syndrome subjects alone did not
show a statistically significant correlation. There was
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22
Male
43  2
35.1  0.8
115  3
68.3  1.5
42.4  2.0
26.5  0.7
5.8  0.1
100  14
5.1  0.1
439  49
158  16
37  2
122  7
66  3
2.39  0.25

0.208
<0.001
<0.001
<0.001
<0.001
<0.001
0.053
<0.001
0.880
0.278
0.524
0.569
0.073
0.161
<0.001

A

7
Male
38  4
24.7  1.0
95  4
56.3  2.7
21.2  4.3
33.6  1.2
5.3  0.3
51  14
5.1  0.2
370  27
154  44
39  4
98  10
57  4
5.68  0.53

Sedentary
controls

Metabolic
syndrome

P value
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Years
kg/m2
cm
kg
kg
mL/kg.min
mmol/L
pmol/L
mmol/L
pmol/L
mg/dL
mg/dL
mg/dL
U/L
mg/kg.min
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*data are displayed as mean  standard error, SSGIR steady-state glucose infusion rate.

0.294
<0.001
<0.001
<0.001
<0.001
<0.001
0.075
<0.001
0.829
0.520
0.022
<0.001
0.192
0.060
<0.001
11
Female
44  3
34.2  0.8
114  2
50.5  1.5
41.9  2.9
21.2  1.1
5.5  0.2
83  11
4.9  0.1
373  38
196  49
44  2
114  12
74  5
2.20  0.27
10
Female
39  4
23.7  1.2
90  4
41.9  1.3
20.1  2.4
28.9  2.2
4.9  0.2
42  7
4.8  0.1
355  42
108  20
57  2
91  7
58  6
6.29  0.67
33
11F/22M
43  2
34.8  0.6
114  2
62.7  1.9
42.3  1.6
25.2  0.8
5.7  0.1
94  10
5.0  0.1
404  31
171  19
39  1
120  6
69  3
2.32  0.19
Number of subjects
Gender
Age
BMI
Waist
Lean body mass
Fat mass
VO2max
Fasting glucose
Fasting insulin
Clamp final glucose
Clamp final insulin
Serum triglycerides
Serum HDL
Serum LDL
Serum AP
SSGIR

17
10F/7M
38  3
24.1  0.8
92  3
47.3  2.2
20.5  2.1
31.0  1.5
5.1  0.2
46  7
4.9  0.1
362  27
127  22
50  3
94  6
58  4
6.04  0.44

0.108
<0.001
<0.001
<0.001
<0.001
<0.001
0.004
<0.001
0.689
0.274
0.019
0.002
0.008
0.025
<0.001

Metabolic
syndrome
Metabolic
syndrome
Sedentary
controls
Units

Table 1. Subject characteristics*.

P value

Sedentary
controls

P value

B

Figure 1. IRS-1 content of muscle from metabolic syndrome
subjects. (Panel A) shows sample immunoblots for each of the
antibodies used for quantifying total IRS-1 and phosphorylation at
six specific sites. Each blot shown here had lanes containing
samples from metabolic syndrome subjects alternating with samples
from controls. The band on the left of each image shown is a
metabolic syndrome subject. Panel B summarizes the data for each
antibody. All of the data are expressed in relation to the mean of
the untrained sedentary control subjects for each assay. The data
displayed are the mean and standard errors from at least two
separate assays for each subject. The number of subjects that had
complete data in each assay was variable due to sample limitations.
The data shown in Panel B represent 10–12 controls and 14–18
metabolic syndrome subjects. The asterisk indicates significant
difference (P < 0.05, t test) from the control subject data for that
assay.

considerable overlap between the controls and the metabolic syndrome subjects, but about half of the metabolic
syndrome subjects had much higher Ser636 phosphorylation. The statistical correlation is dependent on including
the control data. Indeed, this suggests that excess Ser636
phosphorylation may be important in some, but does not
account for all of the insulin resistance among the metabolic syndrome subjects. The correlation of SSGIR with
phosphorylation at Ser337 was significant only in the

ª 2014 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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Figure 2. The effect of exercise training on muscle IRS-1
phosphorylation at Ser337 and Ser636. Pre- and postexercise
training data are displayed in this figure. Eight weeks of training,
either progressive resistance or a stationary bike program, did not
significantly alter the level of baseline phosphorylation of Ser337 or
Ser636 as quantified by western blots. Shown here are the mean
and standard errors of results of at least two separate experiments
including pre- and posttraining muscle specimens from 12 controls
and 18 metabolic syndrome subjects. The asterisk denotes
significant difference (P < 0.05) from the corresponding control
data. There was no significant increase or decrease in
phosphorylation of Ser337 or Ser636 after exercise training in
controls or metabolic syndrome subjects.

pretraining data (R = 0.398, P = 0.049, n = 25). Total
IRS-1, pTyr896, pSer307, pSer789, and pSer1101 did not
correlate with SSGIR or fasting insulin concentration.

Discussion
The insulin resistance of the metabolic syndrome subjects
in this study was dramatic. The metabolic syndrome insulin responsiveness quantified by euglycemic insulin clamp
studies was less than half that seen in age- and gendermatched sedentary control subjects. Previous studies
found that in spite of severe insulin resistance, muscle
insulin receptor and GLUT4 expression were normal
(Stuart et al. 2013). In fact, exercise interventions
increased insulin receptor and GLUT4 expression but did
not improve whole-body insulin responsiveness, suggesting that an intermediate step in insulin stimulation of glucose uptake was impaired (Layne et al. 2011; Stuart et al.
2013). This study found that total IRS-1 expression was
not decreased in metabolic syndrome subjects, nor was
baseline tyrosine phosphorylation at Tyr896. Immunoblots
using antibodies directed at specific phosphorylated sites

Muscle IRS-1 in the Metabolic Syndrome

Figure 3. Correlation between insulin responsiveness and baseline
phosphorylation at IRS-1 serine 636. The data shown are the
euglycemic clamp steady-state glucose infusion rate (SSGIR) plotted
against the relative amount of phosphorylation at IRS-1 serine 636.
The data shown are before and/or after training for 11 controls
(open symbols) and 20 metabolic syndrome subjects (filled circles).
The missing subjects had inadequate muscle left for this assay to be
done. The correlation coefficient (R) and p value, calculated using
Pearson Product Moment, are shown on the graph.

showed that the baseline phosphorylation status of serines
at sites 337 and 636 were increased compared with control
subjects.
JNK1 and mTOR-S6K1 phosphorylate both Ser307 and
Ser636 and a few others. GSK3 specifically phosphorylates
IRS-1 at Ser337. The IRS-1 serine at position 789, a target
for AMPK, was not different in metabolic syndrome subjects. Phosphorylations of IRS-1 at Ser307 (a target of
JNK and IKK) and Ser1101 (a target of PKCh) were not
increased in metabolic syndrome muscle. Exercise training
for 8 weeks with no weight loss did not improve insulin
responsiveness in euglycemic clamp studies and the baseline phosphorylation status of Ser337 and Ser636 in metabolic syndrome muscle was unchanged.
In skeletal muscle, IRS-1 is phosphorylated at tyrosine
896 by the insulin-activated tyrosine kinase within the
beta subunit of the insulin receptor (Saltiel and Kahn
2001). Insulin and insulin-like growth factor-1 (IGF-1)
act as growth factors through their respective cell surface
receptors via tyrosine phosphorylation of IRS-1, which in
turn associates the catalytic and regulatory subunits of
phosphatidylinositol-3 kinase (PI-3K) resulting in the
phosphorylation of phosphatidylinositol bis-phosphate
(PIP2), thereby generating PIP3, the principal intracellular
mediator of insulin action (LeBrasseur et al. 2011). PIP3
causes assembly of Src and Akt on b-arrestin-2 scaffolding, activating Akt (Luan et al. 2009), at least one isoform
of which is critical in GLUT4 translocation (Wilson and
Rotwein 2007).
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Phosphorylation of IRS-1 at one or more of several key
serines acts to terminate the insulin signal by ending the
association of the PI-3K subunits on IRS-1. Insulin itself
may eventually terminate its action on glucose uptake by
phosphorylation of IRS-1 at one or more serines by
several kinases that are activated directly or indirectly by
PIP3 (De and Roth 1997; Ozes et al. 2001; Liberman and
Eldar-Finkelman 2005). Additional kinases that mediate
inflammation and stimulation of protein synthesis by
insulin and other growth factors may play a role in terminating or limiting insulin-stimulated PI-3K activation.
Activation of the protein synthetic muscle hypertrophy
pathway by resistance training or growth factors involves
phosphorylation and activation of the mammalian target
of rapamycin (mTOR). IRS-1 is phosphorylated at Ser636
by S6K1 which is activated by mTOR. This serine phosphorylation inactivates PI-3K and limits insulin stimulation of protein synthesis by this negative feedback loop
(De and Roth 1997; Ozes et al. 2001). Insulin stimulates
glycogen synthase at least in part by decreasing its serine
phosphorylation through inhibition of glycogen synthase
kinase-3 (GSK3). The apparent phosphorylation of IRS-1
at Ser337 by GSK3 may also act as a negative feedback
loop to turn off insulin-stimulated activation of PI-3Krelated stimulation of glucose uptake and glycogen synthesis (Liberman and Eldar-Finkelman 2005). Nikoulina and
coworkers have shown that the GSK3 activity was nearly
doubled in skeletal muscle from type 2 diabetes subjects
coincident with lower activity of glycogen synthase compared with lean and obese nondiabetic subjects (Nikoulina
et al. 2000). They also found that higher GSK3 activity
was associated with lower insulin-stimulated glucose disposal rates during euglycemic clamps in their subjects.
JNK has also been demonstrated to act by phosphorylation of IRS-1 at Ser636, a site that was robustly hyperphosphorylated in our metabolic syndrome subjects’
muscle. In spite of 8 weeks of exercise training, the hyperphosphorylation at Ser636 was unchanged, which is
consistent with the fact that the amount of adipose tissue
in each subject was also unchanged after training.
Another potential site of IRS-1 serine phosphorylation
that could mediate insulin resistance was at Ser1101. Li
and coworkers demonstrated that PKCh-mediated phosphorylation at Ser1101 inhibited insulin stimulation of
glucose uptake (Li et al. 2004). Phosphorylation at
Ser1101 inhibited tyrosine phosphorylation of IRS-1 in
response to insulin and thus effects downstream of IRS-1
were diminished (Li et al. 2004). Our studies did not find
excess phosphorylation at this site.
Direct evidence of IRS-1 being the critical site of
impaired insulin action in human obesity and type 2
diabetes has been elusive. Searches for abnormalities in IRS1 primary structure have identified three polymorphisms
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that affect 10–15% of patients with type 2 diabetes, but
essentially the same prevalence of these substitutions was
found in control subjects (Laakso et al. 1994; Sigal et al.
1996). The most frequent polymorphism was a G to A substitution in the gene sequence that caused a glycine to arginine amino acid change at codon 792 (Gly792Arg
polymorphism).
Hribal
and
coworkers
over
expressed Arg792-IRS-1 in L6 skeletal muscle cells and demonstrated diminished insulin action including less PI-3K
activation, less phosphorylation of AKT, less translocation
of GLUT1 and GLUT4, and less glucose uptake into the cells
(Hribal et al. 2000). These data suggest a possible role of
altered primary structure of IRS-1 in developing the insulin
resistance of the metabolic syndrome and type 2 diabetes is
rare and does not contribute to the mechanisms of the vast
majority of subjects with insulin resistance.
Studies in mice and in cell culture have shown multiple
activated protein kinases phosphorylate IRS-1 on serines
that dampen the insulin signal (Boura-Halfon and Zick
2009). Yi and coworkers have shown that insulin causes
increased phosphorylation of at least six IRS-1 serines
and a decrease in phosphorylation of two serines and two
threonines in muscle from normal subjects (Yi et al.
2007). The insulin resistance of obesity is at least partly
due to adipocyte-produced cytokines which circulate and
interact with muscle cell surface JAK receptors (Johnston
et al. 2003). Subsequent involvement of intracellular
STAT and JNK systems have been shown directly or indirectly through mTOR/S6K1 to cause increased phosphorylation of multiple IRS-1 serines (307, 337, 636, 1101).
Our immunoblot data using antibodies against phosphoserines found increased basal phosphorylation of Ser337
and Ser636, but no increase in phosphorylation at Ser307
or Ser1101. Ser636 hyperphosphorylation may be due to
inflammation, activation of mTOR, or both. Excess phosphorylation of Ser337 suggests that GSK3 activation may
also be involved in the inhibition of transmittal of the
insulin signal downstream of IRS-1.
The baseline hyperphosphorylation of IRS-1 at Ser337
and Ser636 coincides with the diminished glucose uptake
into the muscle in response to increments in blood insulin concentrations in many of the metabolic syndrome
subjects. The higher significant negative correlation
between insulin responsiveness and phosphorylation at
Ser636 suggests that this site may be the more important
of the two sites that had excess phosphorylation. Previous
reports have shown that excess phosphorylation at Ser337
by GSK3 or at Ser636 by JNK1 and phospho-mTOR can
cause insulin resistance by preventing insulin receptormediated tyrosine phosphorylation of IRS-1 (Ozes et al.
2001; Liberman and Eldar-Finkelman 2005). Our data
showed only a small decrease in muscle IRS-1 baseline
Tyr896 phosphorylation in metabolic syndrome subjects
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suggesting, at least in the fasted situation, tyrosine phosphorylation was adequate (albeit with a more than twofold higher insulin concentration). We did not measure
IRS-1 tyrosine phosphorylation after the euglycemic
clamp insulin infusion, but based on studies by other
groups in mice (Aguirre et al. 2002; Boura-Halfon and
Zick 2009), we infer that insulin-stimulated phosphorylation of IRS-1 at Tyr896 is likely impaired in the metabolic
syndrome subjects with fasting hyperphosphorylation of
IRS-1 at Ser636 and/or Ser337. Activation of GSK3 or
JNK1 was not quantified in these subjects, but previously
we reported that baseline phospho-mTOR was not
increased in metabolic syndrome subjects, although post
resistance training the increase in mTOR activation was
nearly twice that of the control subjects (Layne et al.
2011). Disappointedly, exercise training without weight
loss did not diminish the basal level of IRS-1 serine excess
phosphorylation or improve insulin responsiveness. In
our previous reports, resistance training increased
strength in metabolic syndrome volunteers by 28% (Layne
et al. 2011) and stationary bike training increased aerobic
fitness (VO2max) by 16% (Stuart et al. 2013), but the fat
mass averaged close to 20 kg and did not change.

Conclusion
These data suggest that in metabolic syndrome muscle,
serine phosphorylation of IRS-1, the physiological negative feedback that normally turns off the insulin signal, is
already partially in effect in many of these subjects before
insulin concentrations are augmented in response to a
meal or exogenous insulin.
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